HRP20220263T1 - Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi - Google Patents
Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi Download PDFInfo
- Publication number
- HRP20220263T1 HRP20220263T1 HRP20220263TT HRP20220263T HRP20220263T1 HR P20220263 T1 HRP20220263 T1 HR P20220263T1 HR P20220263T T HRP20220263T T HR P20220263TT HR P20220263 T HRP20220263 T HR P20220263T HR P20220263 T1 HRP20220263 T1 HR P20220263T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- image
- pharmaceutically acceptable
- phenyl
- methyl
- Prior art date
Links
- -1 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- HLLGQFADOTVZQN-LJQANCHMSA-N (2R)-N-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-3-methylphenyl]-2-(3-fluorophenyl)-2-hydroxyacetamide Chemical compound NC=1C2=C(N=CN=1)N(C=C2C1=C(C=C(C=C1)NC([C@H](O)C1=CC(=CC=C1)F)=O)C)C HLLGQFADOTVZQN-LJQANCHMSA-N 0.000 claims 1
- BRIWRAFDHZTJPE-OAQYLSRUSA-N 2-amino-5-[4-[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-2-methylphenyl]-N-propan-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC(C)C)C1=C(C=C(C=C1)NC([C@H](O)C1=CC(=CC(=C1)F)F)=O)C BRIWRAFDHZTJPE-OAQYLSRUSA-N 0.000 claims 1
- WFLLOUGNTSBEON-GOSISDBHSA-N 3-amino-6-[4-[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-2-methylphenyl]-N-methylpyrazine-2-carboxamide Chemical compound NC=1C(=NC(=CN=1)C1=C(C=C(C=C1)NC([C@H](O)C1=CC(=CC(=C1)F)F)=O)C)C(=O)NC WFLLOUGNTSBEON-GOSISDBHSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Claims (11)
1. Spoj formule
[image]
naznačen time što
R je odabran iz grupe koja se sastoji od
[image]
X je CH ili N;
R1 je vodik ili fluoro; i
R2 je C1 do C3 alkil;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, formule
[image]
naznačen time što
R je odabran iz grupe koja se sastoji od
[image]
X je CH ili N;
R1 je vodik ili fluoro; i
R2 je C1 do C3 alkil;
ili njegova farmaceutski prihvatljiva sol.
3. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 ili 2 naznačen time što, R je
[image]
4. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 ili 2 naznačen time što,
X je CH ili N;
R1 is vodik ili fluoro; i
R2 je metil ili izopropil.
5. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 ili 2 naznačen time što, R je
[image]
6. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 koji je 3-amino-6-[4-[[(2R)-2-(3,5-difluorofenil)-2-hidroksi-acetil]amino]-2-metil-fenil]-N-metilpirazin-2-karboksamid, koji je predstavljen formulom
[image]
ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 koji je 2-amino-5-[4-[[(2R)-2-(3,5-difluorofenil)-2-hidroksi-acetil]amino]-2-metil-fenil]-N-izopropil-piridin-3-karboksamid, koji je predstavljen formulom
[image]
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 koji je (2R)-N-[4-(4-amino-7-metil-pirolo[2,3-d]pirimidin-5-il)-3-metil-fenil]-2-(3-fluorofenil)-2-hidroksi-acetamid, koji je predstavljen formulom
[image]
ili njegova farmaceutski prihvatljiva sol.
9. Farmaceutska kompozicija koja sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od patentnih zahtjeva 1-8, sa jednim ili više farmaceutski prihvatljivih nosača, razblaživača ili ekscipijenasa.
10. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1-8, za uporabu u terapiji.
11. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1-8, za uporabu u liječenju raka gušterače.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17382207 | 2017-04-18 | ||
EP18718570.7A EP3612519B1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
PCT/US2018/027005 WO2018194885A1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220263T1 true HRP20220263T1 (hr) | 2022-04-29 |
Family
ID=58606227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220263TT HRP20220263T1 (hr) | 2017-04-18 | 2018-04-11 | Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi |
Country Status (28)
Country | Link |
---|---|
US (2) | US11655214B2 (hr) |
EP (2) | EP4039675B1 (hr) |
JP (2) | JP7110232B2 (hr) |
KR (2) | KR20230129627A (hr) |
CN (2) | CN110831927B (hr) |
AU (2) | AU2018255191B2 (hr) |
BR (1) | BR112019021867A2 (hr) |
CA (1) | CA3060564A1 (hr) |
CO (1) | CO2019012767A2 (hr) |
CR (1) | CR20190519A (hr) |
CY (1) | CY1125150T1 (hr) |
DK (2) | DK4039675T3 (hr) |
ES (1) | ES2906847T3 (hr) |
FI (1) | FI4039675T3 (hr) |
HR (1) | HRP20220263T1 (hr) |
HU (1) | HUE057745T2 (hr) |
IL (2) | IL270005B (hr) |
LT (2) | LT4039675T (hr) |
MX (2) | MX2019012428A (hr) |
PH (1) | PH12019502363A1 (hr) |
PL (1) | PL3612519T3 (hr) |
PT (2) | PT3612519T (hr) |
RS (2) | RS62933B1 (hr) |
SA (1) | SA519410320B1 (hr) |
SG (1) | SG11201909680UA (hr) |
SI (2) | SI4039675T1 (hr) |
WO (1) | WO2018194885A1 (hr) |
ZA (1) | ZA201906811B (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019021867A2 (pt) | 2017-04-18 | 2020-05-26 | Eli Lilly And Company | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil |
EA202092282A1 (ru) * | 2018-03-26 | 2021-01-14 | Икан Скул Оф Медсин Эт Маунт Синай | Способы лечения минимального остаточного рака |
WO2021041970A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
WO2021041975A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
US20220348584A1 (en) | 2019-08-29 | 2022-11-03 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
CN113234029B (zh) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | 一种2-氨基-3,5-二卤代吡嗪的合成方法 |
WO2024206890A1 (en) * | 2023-03-30 | 2024-10-03 | Hibercell, Inc. | Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
KR20000076426A (ko) | 1997-03-19 | 2000-12-26 | 스타르크, 카르크 | 피롤로[2,3-d]피리미딘 및 티로신 키나제 저해제로서의 그의 용도 |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
CA2484209C (en) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
CN1856469B (zh) | 2003-07-23 | 2013-03-06 | 拜耳医药保健有限责任公司 | 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲 |
PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
CA2620818A1 (en) * | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
WO2009108637A1 (en) | 2008-02-25 | 2009-09-03 | Prometheus Laboratories, Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
CA2794153C (en) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
EP2986286A1 (en) | 2013-04-15 | 2016-02-24 | Universita' Degli Studi di Bari | Galloyl benzamide-based compounds as jnk modulators |
WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
EP3067356B1 (en) | 2013-11-08 | 2018-07-04 | ONO Pharmaceutical Co., Ltd. | Pyrrolo pyrimidine derivative |
EP3116877A1 (en) | 2014-03-11 | 2017-01-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Chemical compounds acting as perk inhibitors |
WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
JP6421241B2 (ja) | 2014-11-14 | 2018-11-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | タンパク質キナーゼ阻害剤としての6−アミノ−7−ビシクロ−7−デアザ−プリン誘導体 |
GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
CN108026102A (zh) * | 2015-07-24 | 2018-05-11 | 蓝印药品公司 | 可用于治疗与kit和pdgfr相关的病症的化合物 |
US10399988B2 (en) | 2016-07-07 | 2019-09-03 | Daewoong Pharmaceutical Co., Ltd. | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same |
CA3031047A1 (en) | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
CN106748989B (zh) | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
WO2018138358A1 (en) | 2017-01-30 | 2018-08-02 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
BR112019021867A2 (pt) | 2017-04-18 | 2020-05-26 | Eli Lilly And Company | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil |
US11673891B2 (en) | 2017-11-14 | 2023-06-13 | Dana-Farber Cancer Institute, Inc. | Imidazopyrimidine compounds and uses thereof |
EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
EA202092282A1 (ru) | 2018-03-26 | 2021-01-14 | Икан Скул Оф Медсин Эт Маунт Синай | Способы лечения минимального остаточного рака |
CA3104398A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
EP3860578A1 (en) | 2018-10-01 | 2021-08-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt unknown
- 2018-04-11 LT LTEP21211015.9T patent/LT4039675T/lt unknown
- 2018-04-11 FI FIEP21211015.9T patent/FI4039675T3/fi active
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 MX MX2019012428A patent/MX2019012428A/es unknown
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 CA CA3060564A patent/CA3060564A1/en active Pending
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 EP EP21211015.9A patent/EP4039675B1/en active Active
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 RS RS20240950A patent/RS65914B1/sr unknown
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en active Application Filing
- 2018-04-11 DK DK21211015.9T patent/DK4039675T3/da active
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Application Discontinuation
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 SI SI201831149T patent/SI4039675T1/sl unknown
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active IP Right Grant
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 PT PT212110159T patent/PT4039675T/pt unknown
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-10-17 PH PH12019502363A patent/PH12019502363A1/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US20230373922A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220263T1 (hr) | Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi | |
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
EA034243B9 (ru) | Фармацевтические композиции, содержащие azd9291, для лечения рака | |
GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
RU2019106484A (ru) | Гетероциклическое соединение | |
PE20151091A1 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes | |
BR112014025564A2 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo | |
EA201500953A1 (ru) | 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений | |
NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
GEP20247646B (en) | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | |
RU2018147263A (ru) | Фторированные 2-амино-4-(замещенные амино)фенилкарбаматные производные | |
JP2016501185A5 (hr) | ||
PH12016502353A1 (en) | Pharmaceutical composition | |
MX2019010695A (es) | Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones. | |
PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
MX2018006225A (es) | Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). | |
EA201692298A1 (ru) | Производные карбоксамидов | |
EA201492081A1 (ru) | (r)-нифурател, его применение в лечении инфекций и синтез (r)- и (s)-нифуратела | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
PH12015501945B1 (en) | Formulations of organic compounds |